THE FDA has prioritised approvals for generic and biosimilar drugs to increase competition and is highlighting its success in the face of tighter US national budgets.
With the strengthening and streamlining of the generic drug review process, FDA Commissioner Scott Gottlieb said the regulatory body had achieved record numbers for approvals and tentative approvals for generics in 2017-18.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Feb 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Feb 19